Cutting Edge Information’s Research Shows Market for Breast Cancer Drugs to Top $40 Billion by 2012

RESEARCH TRIANGLE PARK, NC–(EMWNews – August 15, 2008) – The finding comes out of a new

study released by market intelligence firm Cutting Edge Information.

According to Cutting Edge Information’s research, total oncology sales will

grow by 56% between 2007 and 2012. 2007 sales amounted to approximately

$18 billion.

The new report, “The Oncology Market Forecast to 2013,” is a comprehensive

study of more than 135 oncology drugs. The study takes a close look at the

market for five major oncology indications, including colorectal, leukemia,

lung, prostate and breast cancer. It also includes detailed forecasts for

each drug, including forecasts for individual drug classes and top oncology

drug manufacturers

(http://www.cuttingedgeinfo.com/oncology/TA220_Download.asp).

The market outlook for breast cancer treatments is bright indeed. Roche’s

and Genentech’s blockbusters Avastin and Herceptin are currently undergoing

clinical testing for cancer treatment. Meanwhile, several developmental

drugs — including Novartis’ Gleevec — are poised to take on the breast

cancer market within the next couple of years. Gleevec is in Phase 3

trials for advanced breast cancer, and is expected to be a boon for

Novartis on the order of several billion in annual sales.

“The market for breast cancer treatment is certainly on an upward

trajectory,” said Eric Bolesh, lead author of the study. “Several

promising therapies are in the pipeline, and the options for treatment are

ever-expanding — which is good news for the industry and for patients.”

The 420+ page study examines 17 monoclonal antibodies and more than 120

other drugs, and provides the following market analysis:

--  Individual Drug Profiles - Drug profiles include information about

    drugs' competitive, strategic and market growth positions.

--  Oncology Indication Market Outlook - Detailed outlooks for the breast,

    colorectal, lung and prostate cancer and leukemia markets.

--  Company Profiles - Oncology breakdowns for companies that either have

    established oncology franchises or exciting development pipelines for new

    cancer compounds.